A shadow market for unlicensed weight-loss medications is being driven by social media fitness personalities and sellers on communication apps, based on recent findings.
Experimental Treatment Gaining Popularity Via Social Media
The experimental drug, which remains in clinical trials, is being promoted by online personalities for its supposed weight-reducing effects. Viewers are encouraged to message these accounts privately for supplier links, while also obtaining discount codes.
Active Trade on Messaging Platforms
Separately, a flourishing market exists on messaging services, where groups with thousands of participants share comparison photos, administration instructions and claims of rapid UK delivery. Sellers promote the drug there before redirecting buyers to other platforms for purchases.
Learning About Retatrutide
Retatrutide is an experimental injection developed by American pharmaceutical company Eli Lilly. The drug affects three intestinal hormones – glucagon-like peptide-1, GIP and glucagon. Early trials suggest it could help patients lose up to a quarter of their total weight. Referred to as the “triple G”, the substance is being hailed online as the next Ozempic.
Medical Experts Express Concerns
However, doctors and chemists have warned that the distribution of what remains an unapproved drug in the United Kingdom is worrisome and could result in users administering substances of unknown origin.
Several experts stated the demand for the experimental drug could be connected to the increasing price of approved weight loss treatments such as Mounjaro.
Legal Status and Enforcement
Selling the unapproved drug on TikTok or Telegram is illegal in the United Kingdom, as it is an unapproved drug that must not be promoted or supplied for personal consumption under the British medical regulations.
Some influencers attempt to sidestep the regulations by calling to the drug as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a controlled drug, but advertising and distribution can still breach pharmaceutical, marketing, and customer laws, potentially leading to fines, legal action or imprisonment.
Service Response and Material Elimination
According to the social media company, the service has taken down violative content and banned associated keywords and search suggestions. The organization said it was committed to maintaining the service safe and investing in enhancing compliance measures.
Online Marketplace Operations
Investigations also found communities with up to nine thousand participants selling retatrutide using Telegram's integrated search feature, which operates like a online catalog. Entering “retatrutide” immediately displays groups with thousands of users, populated with photos of weight loss, positive testimonials and step-by-step guides for preparing or administering at home.
Within minutes of entering one community, a vendor posted contact information, where most purchases take place. The seller sent an instruction manual and guaranteed delivery within two days. When questioned whether the product was authentic, one seller said: “You can’t be sure.” Another provided a image of a alleged laboratory certificate. Not one inquired about weight, medical conditions or previous experience.
Item Details and Pricing
Within these groups, posts display dark colored parcels with Royal Mail stickers, stating to include fresh supplies. One communication stated: “It took eight of us to load them this morning.”
Buyers can choose between powder vials, mixed at residence with sterile water, or pre-filled injectors typically priced at £160 for 20 milligrams. When asked how much time a pen should be used, vendors give contradictory answers ranging from a several days to “depends on your body”.
Service Oversight and Safety Actions
A spokesperson for Telegram stated it regularly monitored dangerous content on its platform including material that promoted the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.
Healthcare Expert Warnings
“Individuals are injecting substances they cannot confirm. Even if the research behind retatrutide is valid, these digital products may not include what they advertise,” said Jason Murphy, the director of pharmaceutical services at a pharmacy service.
Dr Crystal Wyllie of Asda Online Doctor linked the surge in interest to current price rises for approved slimming drugs such as Mounjaro. “With costs rising, individuals are using social media. But counterfeit treatments are highly risky. You can’t be certain what’s inside or whether the environment they were made in was clean,” she said.
Her staff has already seen individuals injured by self-injection from unconfirmed suppliers. “We understand the frustration, but buying from Telegram or WhatsApp is gambling with your well-being,” stated the doctor. “These substances could be contaminated or improperly measured.”
Manufacturer Position
A representative from Eli Lilly stated retatrutide was in phase 3 clinical trials and had not been reviewed or authorized by any government authority globally. “Consequently at this time no one can sell [it] for personal consumption,” they explained, adding that any item “misleadingly claiming itself as a Lilly experimental product not yet approved … may subject patients to potentially serious health risks”.